Perspective Therapeutics, Inc.
CATX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $206 | $221 | $136 | $170 |
| - Cash | $62 | $9 | $21 | $60 |
| + Debt | $4 | $3 | $0 | $1 |
| Enterprise Value | $148 | $214 | $115 | $110 |
| Revenue | $0 | $1 | $7 | $11 |
| % Growth | -100% | -79.8% | -34.2% | – |
| Gross Profit | $0 | $1 | $2 | $5 |
| % Margin | – | 100% | 23% | 42.8% |
| EBITDA | $10 | -$40 | -$15 | -$7 |
| % Margin | – | -2,786.6% | -208.9% | -68.5% |
| Net Income | -$79 | -$47 | -$15 | -$7 |
| % Margin | – | -3,243.2% | -206.5% | -66.3% |
| EPS Diluted | -1.23 | -0.85 | -0.27 | -0.13 |
| % Growth | -44.7% | -214.8% | -107.7% | – |
| Operating Cash Flow | -$18 | -$37 | -$12 | -$8 |
| Capital Expenditures | -$54 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$73 | -$38 | -$12 | -$8 |